{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:01:14Z","timestamp":1793106074730,"version":"4.5.0"},"reference-count":29,"publisher":"The Endocrine Society","issue":"7","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK 06950"],"award-info":[{"award-number":["DK 06950"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK32333"],"award-info":[{"award-number":["DK32333"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009210","name":"Food and Drug Administration","doi-asserted-by":"publisher","award":["FDA 002525"],"award-info":[{"award-number":["FDA 002525"]}],"id":[{"id":"10.13039\/100009210","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Calcium and vitamin D treatment does not improve reduced quality of life (QOL) in hypoparathyroidism. Recombinant human (rh) PTH(1-84) therapy improves QOL metrics for up to 5 years. Data on QOL beyond this time point are not available.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the effects of 8 years of rhPTH(1-84) therapy on QOL and factors associated with long-term benefit.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Prospective, open-label trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Referral center.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients<\/jats:title>\n                  <jats:p>Twenty patients with hypoparathyoidism.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>RAND 36-Item Short Form Health Survey (SF-36).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>rhPTH therapy led to substantial improvement in five of the eight SF-36 domains [vitality, social functioning (SF), mental health (MH), bodily pain (BP) and general health] and three of these domains (SF, MH, BP) were no longer lower than the reference population. The improvement in the mental component summary (MCS) score was sustained through 8 years, while the physical component summary (PCS) score improved through 6 years. A lower baseline QOL score was associated with greater improvement. A threshold value &amp;lt;238 (MCS) and &amp;lt;245 (PCS) predicted long-term improvement in 90% and 100% of the cohort, respectively. In patients whose calcium supplementation was reduced, MCS and PCS scores improved more than those whose supplementation did not decline to the same extent. Improvement in PCS was greater in patients whose calcitriol dosage was reduced and duration of disease was shorter.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>rhPTH(1-84) improves long-term well-being in hypoparathyroidism. The improvements are most prominent in those with impaired SF-36 at baseline and those whose requirements for conventional therapy decreased substantially.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2018-02430","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T20:06:08Z","timestamp":1550520368000},"page":"2748-2756","source":"Crossref","is-referenced-by-count":61,"title":["Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy"],"prefix":"10.1210","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6808-0700","authenticated-orcid":false,"given":"Gaia","family":"Tabacco","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, College of Physicians & Surgeons, Columbia University, New York, New York"},{"name":"Unit of Endocrinology and Diabetes, Department of Medicine, University Campus Bio-Medico, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Kwang Donovan","family":"Tay","sequence":"additional","affiliation":[{"name":"Department of Medicine, Sengkang General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie E","family":"Cusano","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, Lenox Hill Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Williams","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, College of Physicians & Surgeons, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Omeragic","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, College of Physicians & Surgeons, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukhana","family":"Majeed","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, College of Physicians & Surgeons, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximo Gomez","family":"Almonte","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Wyckoff Heights Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mishaela R","family":"Rubin","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, College of Physicians & Surgeons, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"Bilezikian","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, College of Physicians & Surgeons, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,2,18]]},"reference":[{"issue":"12","key":"2020071623440792500_B1","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1210\/jc.2012-1808","article-title":"Long-term follow-up of patients with hypoparathyroidism","volume":"97","author":"Mitchell","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2020071623440792500_B2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s12020-012-9618-y","article-title":"Mini-review: new therapeutic options in hypoparathyroidism","volume":"41","author":"Cusano","year":"2012","journal-title":"Endocrine"},{"issue":"4","key":"2020071623440792500_B3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMcp0803050","volume":"359","author":"Shoback","year":"2008","journal-title":"N Engl J Med"},{"issue":"10","key":"2020071623440792500_B4","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/jbmr.483","article-title":"Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research","volume":"26","author":"Bilezikian","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2020071623440792500_B5","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1210\/jc.2002-021736","article-title":"Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium","volume":"88","author":"Winer","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2020071623440792500_B6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","article-title":"Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism","volume":"276","author":"Winer","year":"1996","journal-title":"JAMA"},{"issue":"7","key":"2020071623440792500_B7","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1210\/jc.2015-4135","article-title":"Therapy of hypoparathyroidism with PTH(1-84): a prospective six year investigation of efficacy and safety","volume":"101","author":"Rubin","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2020071623440792500_B8","first-page":"e3","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study [published correction appears in","volume":"2","author":"Mannstadt","year":"2014","journal-title":": Lancet Diabetes Endocrinol"},{"issue":"1","key":"2020071623440792500_B9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12020-016-1141-0","article-title":"Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study","volume":"55","author":"Clarke","year":"2017","journal-title":"Endocrine"},{"issue":"1","key":"2020071623440792500_B10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1210\/jc.2017-01555","article-title":"PTH(1-34) for surgical hypoparathyroidism: a 2-year prospective, open-labeliInvestigation of efficacy and quality of life","volume":"103","author":"Palermo","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2020071623440792500_B11","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00198-014-2677-6","article-title":"Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial","volume":"25","author":"Sikjaer","year":"2014","journal-title":"Osteoporos Int"},{"issue":"2","key":"2020071623440792500_B12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1530\/eje.0.1460215","article-title":"Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D","volume":"146","author":"Arlt","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2020071623440792500_B13","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1210\/jc.2015-1855","article-title":"PTH(1-34) for surgical hypoparathyroidism: a prospective, open-label investigation of efficacy and quality of life","volume":"100","author":"Santonati","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2020071623440792500_B14","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1210\/jc.2013-1239","article-title":"The effect of PTH(1-84) on quality of life in hypoparathyroidism","volume":"98","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2020071623440792500_B15","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1210\/jc.2017-01471","article-title":"Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic hypoparathyroidism","volume":"103","author":"Vokes","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2020071623440792500_B16","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00198-009-1149-x","article-title":"Therapy of hypoparathyroidism with intact parathyroid hormone","volume":"21","author":"Rubin","year":"2010","journal-title":"Osteoporos Int"},{"issue":"6","key":"2020071623440792500_B17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-Item Short-Form Health Ssurvey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"issue":"1","key":"2020071623440792500_B18","first-page":"30","article-title":"How does the SF 36 perform in healthy populations? A structured review of longitudinal studies","volume":"4","author":"Obidoa","year":"2010","journal-title":"J Soc Behav Health Sci"},{"issue":"10","key":"2020071623440792500_B19","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1210\/jc.2014-2267","article-title":"PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy","volume":"99","author":"Cusano","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2020071623440792500_B20","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/jbmr.2273","article-title":"Postsurgical hypoparathyroidism\u2014risk of fractures, psychiatric diseases, cancer, cataract, and infections","volume":"29","author":"Underbjerg","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2020071623440792500_B21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12020-017-1377-3","article-title":"Quality of life in patients with hypoparathyroidism receiving standard treatment: a systematic review","volume":"58","author":"B\u00fcttner","year":"2017","journal-title":"Endocrine"},{"issue":"8","key":"2020071623440792500_B22","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1210\/jc.2016-1477","article-title":"Epidemiology and health-related quality of life in hypoparathyroidism in Norway","volume":"101","author":"Astor","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2020071623440792500_B23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.4158\/EP13321.OR","article-title":"Surgeons and patients disagree on the potential consequences from hypoparathyroidism","volume":"20","author":"Cho","year":"2014","journal-title":"Endocr Pract"},{"issue":"2","key":"2020071623440792500_B24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1530\/acta.0.1060227","article-title":"Immunoreactive parathyroid hormone, calcium, and magnesium in human cerebrospinal fluid","volume":"106","author":"Balabanov","year":"1984","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"26","key":"2020071623440792500_B25","doi-asserted-by":"crossref","first-page":"15455","DOI":"10.1074\/jbc.270.26.15455","article-title":"Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor","volume":"270","author":"Usdin","year":"1995","journal-title":"J Biol Chem"},{"key":"2020071623440792500_B26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.physbeh.2017.09.005","article-title":"The parathyroid hormone 2 receptor participates in physiological and behavioral alterations of mother mice","volume":"181","author":"Gell\u00e9n","year":"2017","journal-title":"Physiol Behav"},{"issue":"1","key":"2020071623440792500_B27","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.neuroscience.2009.04.054","article-title":"Parathyroid hormone 2 receptor and its endogenous ligand tuberoinfundibular peptide of 39 residues are concentrated in endocrine, viscerosensory and auditory brain regions in macaque and human","volume":"162","author":"Bag\u00f3","year":"2009","journal-title":"Neuroscience"},{"issue":"7","key":"2020071623440792500_B28","doi-asserted-by":"crossref","first-page":"671","DOI":"10.4158\/EP13328.OR","article-title":"Understanding the burden of illness associated with hypoparathyroidism reported among patients in the PARADOX study","volume":"20","author":"Hadker","year":"2014","journal-title":"Endocr Pract"},{"issue":"6","key":"2020071623440792500_B29","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1210\/jc.2015-3907","article-title":"Management of hypoparathyroidism: summary statement and guidelines","volume":"101","author":"Brandi","year":"2016","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/7\/2748\/28695437\/jc.2018-02430.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/7\/2748\/28695437\/jc.2018-02430.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T13:20:56Z","timestamp":1594992056000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/104\/7\/2748\/5320276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,18]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2018-02430","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2019,2,18]]}}}